Recent events
Recent events tied to this brand in public sources.
Back to profile17 entries
2026
FDA approves Enspryng for thyroid eye disease
The FDA approved Genentech's Enspryng (satralizumab) for adults with thyroid eye disease, making it the first and only at-home subcutaneous option for this patient population.
2026
Anthropic launches Model Hardware Standard (MHS) in research preview
Anthropic released a blog post on August 27 introducing the Model Hardware Standard (MHS) in research preview form. MHS is a unified control and communication standard that lets AI agents operate devices with programmable interfaces, such as microscopes, liquid handlers, robotic arms and quantum computing equipment. Media including Reuters and CNBC interpreted the move as Anthropic's first public entry into embodied intelligence and physical AI. Genentech said that giving AI direct control of multiple heterogeneous lab devices cut the development and run cycle of fully automated dose-response curve experiments to one third of the original.
2022
FDA approves Genentech's VABYSMO
The FDA approved Genentech's VABYSMO (faricimab-svoa) for treatment of wet age-related macular degeneration and diabetic macular edema.
2021
Recursion, Roche and Genentech announce neuroscience and oncology collaboration
Recursion announced a collaboration with Roche and Genentech to use machine learning, high-content screening and Recursion's technology-enabled drug-discovery platform to identify novel targets and advance medicines in neuroscience and an oncology indication. Roche and Genentech may initiate up to 40 programs under the agreement.
2021
Flywheel platform integrated by Roche and Genentech
Flywheel announced that Roche and Genentech had integrated its platform to ingest, classify, standardize, curate and analyze medical imaging data.
2021
Fresenius filed patent review petitions challenging rheumatoid arthritis patents
Fresenius Kabi USA and Fresenius Kabi SwissBioSim filed Inter Partes Review petitions challenging two patents assigned to Chugai, Roche, and Genentech, asserting that the relevant claims were invalid as anticipated or obvious. These are allegations in the petitions, not a reported decision on their merits.
2021
Genentech and Ribometrix establish RNA-targeted drug collaboration
Genentech and Ribometrix agreed to collaborate on discovery and preclinical development programs targeting RNA. Genentech will oversee further development and commercialization; the collaboration includes an upfront payment, milestone payments and royalties.
2020
OneOncology and Genentech announce research partnership
OneOncology and Genentech announced a multi-year strategic partnership to collaborate on clinical trials, scientific research and real-world data studies aimed at advancing personalized cancer care at community oncology centers across the United States.
2020
Roche acquires Enterprise Therapeutics' TMEM16A potentiator portfolio
Roche acquired Enterprise Therapeutics' TMEM16A potentiator portfolio, which will be developed by Genentech, a member of the Roche Group. Enterprise shareholders are eligible for additional contingent payments tied to predetermined milestones.
2020
Imbio and Genentech partner on lung-disease imaging diagnostics
Imbio partnered with Genentech under a multi-year agreement to develop quantitative imaging diagnostics for lung diseases, drawing on Imbio's technical, regulatory and commercial expertise.
2020
Oncimmune and Genentech collaborate on rheumatology trial samples
Oncimmune signed a collaboration with Genentech to profile samples from Genentech's rheumatology clinical trials, including trials for systemic lupus erythematosus.
2020
FDA approves Tecentriq combination for advanced melanoma
The U.S. Food and Drug Administration approved Tecentriq with Cotellic and Zelboraf to treat patients with BRAF V600 mutation-positive advanced melanoma. Genentech announced the approval.
2020
Roche and Blueprint Medicines announce pralsetinib licensing and collaboration agreement
Roche and Blueprint Medicines announced a licensing and collaboration agreement granting Roche exclusive global co-development and commercialisation rights outside the United States, excluding Greater China. Genentech, a Roche Group member, will have US co-commercialisation rights.
2020
FDA approves Genentech’s COVACTA trial
The US FDA approved Genentech to proceed with the COVACTA phase 3 trial evaluating intravenous Actemra plus standard of care in hospitalized adults with severe COVID-19 pneumonia.
2020
Nimble Therapeutics and Genentech announce multi-year collaboration
Nimble Therapeutics announced a multi-year collaboration with Genentech to accelerate the discovery and development of novel peptide-based medicines for targets across a range of diseases. The agreement includes an undisclosed upfront payment to Nimble, with eligibility for downstream milestone payments and royalties.
2019
FDA approves Xofluza for certain high-risk patients
The FDA approved Xofluza for treating patients aged 12 or older who are at high risk for influenza-related complications and have been symptomatic for no more than two days; Genentech announced the approval.
2019
FDA approves Rituxan for pediatric GPA and MPA
The FDA approved Rituxan, in combination with glucocorticoids, to treat granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients aged 2 years and older. Genentech announced the approval.